Cohort | Patients with SI | |||
---|---|---|---|---|
SI only | SI+sepsis | SI+death | ||
At baseline/enrolment | ||||
N | 11 150 | 671 | 135 | 53 |
Age (years) | 55.7 (12.5) | 59.0 (11.6) | 63.8 (10.3) | 68.2 (7.1) |
Sex (female, n (%)) | 8610 (77.2) | 493 (73.5) | 98 (72.6) | 34 (64.2) |
Symptom onset (years before enrolment) | 10.1 (9.1) | 12.2 (9.9) | 15.1 (11.9) | 12.4 (10) |
Rheumatoid factor positive, n (%) | 8026 (72.3) | 527 (78.5) | 115 (85.2) | 44 (83.0) |
CRP (mg/L) | 18.7 (26.2) | 25.8 (35.4) | 31.5 (45.8) | 30.0 (35.2) |
DAS28 | 5.2 (1.3) | 5.5 (1.3) | 5.7 (1.2) | 6.1 (1.3) |
Comorbidities: heart failure, n (%) | 207 (1.9) | 39 (5.8) | 19 (14.1) | 10 (18.9) |
Chronic renal disease, n (%) | 353 (3.2) | 57 (8.5) | 25 (18.5) | 10 (18.9) |
COPD, n (%) | 737 (6.6) | 107 (16.0) | 23 (17.0) | 14 (26.4) |
Diabetes, n (%) | 1024 (9.2) | 109 (16.2) | 35 (25.9) | 15 (28.3) |
Smoking (never, n (%)) | 4813 (43.2) | 290 (43.2) | 52 (38.5) | 20 (37.7) |
No. of previous bDMARDs | ||||
0, n (%) | 8371 (75.1) | 442 (65.9) | 91 (67.4) | 44 (83) |
≥2, n (%) | 1250 (11.2) | 107 (15.9) | 19 (14.1) | 3 (5.7) |
TNFi, n (%) | 5384 (48.3) | 356 (53.1) | 76 (56.3) | 27 (50.9) |
Other bDMARDs, n (%) | 2203 (19.8) | 182 (27.1) | 28 (20.7) | 8 (15.1) |
Glucocorticoids | ||||
<5 mg, n (%) | 3671 (32.9) | 156 (23.3) | 30 (22.2) | 11 (20.8) |
≥10 mg, n (%) | 2256 (20.2) | 181 (26.8) | 34 (25.2) | 14 (26.4) |
At the time of first serious infection: | ||||
Age at SI | – | 60.8 (11.7) | 66.0 (10.1) | 70.5 (7.3) |
CRP mg/L | – | 17.4 (26.4) | 24.3 (36.9) | 17.0 (23.5) |
DAS28 | – | 4.3 (1.5) | 4.6 (1.4) | 4.6 (1.6) |
Comorbidities | ||||
Heart failure, n (%) | – | 46 (6.9) | 21 (15.6) | 19 (35.8) |
Chronic renal disease, n (%) | – | 68 (10.1) | 32 (23.7) | 14 (26.4) |
TNFi, n (%) | – | 297 (44.3) | 44 (32.6) | 14 (26.4) |
Other bDMARDs, n (%) | – | 129 (19.2) | 17 (12.6) | 3 (5.7) |
Glucocorticoids | ||||
<5 mg, n (%) | – | 257 (38.3) | 40 (29.6) | 16 (30.2) |
≥10 mg, n (%) | – | 100 (14.9) | 26 (19.3) | 14 (26.4) |
Other bDMARD (tocilizumab, rituximab, abatacept). Numbers represent mean (sd) or frequencies (%). Amount of missing data: at baseline most frequent missings were found in CRP (5.0%) and DAS28 (3.1%), at the last study visit prior to SI the CRP was missing in 8.9%.
COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; DAS28, disease activity score (28 joint count); DMARD, disease-modifying antirheumatic drug; bDMARD; biologic DMARD; N, number; SI, serious infection; TNFi, tumor necrosis factor-α inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab),